Developability assessment during the selection of novel therapeutic antibodies

Journal of Pharmaceutical Sciences

Volumn 104, Issue 6, 2015, Pages 1885-1898

  Jarasch, Alexander ^a   Koll, Hans ^a   Regula, Joerg T ^a   Bader, Martin ^a   Papadimitriou, Apollon ^a   Kettenberger, Hubert ^a  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

analytical biochemistry; bioinformatics; biotechnology; deamidation; degradation products; immune response; in silico modeling; monoclonal antibody; oxidation; pharmacokinetics

Indexed keywords

ANTIBODY; ASPARAGINE; ASPARTIC ACID; BIOLOGICAL PRODUCT; CYSTEINE; FC RECEPTOR; LYSINE; METHIONINE; THERAPEUTIC ANTIBODY; TRYPTOPHAN; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

BIOLOGICAL THERAPY; COMPUTER MODEL; DRUG DEVELOPMENT; GLYCATION; GLYCOSYLATION; HUMAN; HYDROPHOBICITY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; ISOELECTRIC POINT; NONHUMAN; OXIDATION; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REVIEW; THERMOSTABILITY; VISCOSITY; WORKFLOW; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; IMMUNOLOGY; PROCEDURES; PROTEIN CONFORMATION; PROTEIN STABILITY;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DISCOVERY; GLYCOSYLATION; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN STABILITY;

EID: 84929179769     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24430     Document Type: Article

References (137)

1. Pavlou AK, Belsey MJ,. 2005. The therapeutic antibodies market to 2008. Eur J Pharm Biopharm 59: 389-396.
2. Elvin JG, Couston RG, van der Walle CF,. 2013. Therapeutic antibodies: Market considerations, disease targets and bioprocessing. Int J Pharm 440: 83-98.
3. Carter PJ., 2006. Potent antibody therapeutics by design. Nat Rev Immunol 6: 343-357.
4. Imai K, Takaoka A,. 2006. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6: 714-727.
5. Safdari Y, Farajnia S, Asgharzadeh M, Khalili M,. 2013. Antibody humanization methods-A review and update. Biotechnol Genet Eng Rev 29: 175-186.
6. Strohl WR, Strohl LM,. 2012. Fundamental technologies for antibody engineering. In Therapeutic antibody engineering: Current and future advances driving the strongest growth area in the pharmaceutical industry. Woodhead Publishing, Cambridge, United Kingdom. pp 57-76.
7. An Z., 2009. Therapeutic monoclonal antibodies: From bench to clinic. Hoboken, New Jersey: John Wiley & Sons.
8. Goding JW., 1996. Production of monoclonal antibodies. In Monoclonal antibodies: Principles and practice. London, United Kingdom, Academic Press. pp 141-191.
9. Tabrizi MA, Klakamp SL, Bornstein GG, SpringerLink (Online service). 2012. Development of antibody-based therapeutics translational considerations. New York: Springer.
10. Carpenter J, Chang B, Garzon-Rodriguez W, Randolph T,. 2002. Rational design of stable lyophilized protein formulations: Theory and practice. In Rational design of stable protein formulations: Theory and practice;, Carpenter JF, Manning MC, Eds. 1st ed. New York: Springer Science+Business Media, pp 109-134.
11. Banta S, Dooley K, Shur O,. 2013. Replacing antibodies: Engineering new binding proteins. Annu Rev Biomed Eng 15: 93-113.
12. Ueda T., 2014. Next-generation optimized biotherapeutics-A review and preclinical study. Biochim Biophys Acta 1844 (11): 2053-2057.
13. Wurch T, Lowe P, Caussanel V, Bes C, Beck A, Corvaia N,. 2008. Development of novel protein scaffolds as alternatives to whole antibodies for imaging and therapy: Status on discovery research and clinical validation. Curr Pharm Biotechnol 9: 502-509.
14. Hawe A, Wiggenhorn M, van de WM, Garbe JH, Mahler HC, Jiskoot W,. 2012. Forced degradation of therapeutic proteins. J Pharm Sci 101: 895-913.
15. Thiel MA, Coster DJ, Standfield SD, Brereton HM, Mavrangelos C, Zola H, Taylor S, Yusim A, Williams KA,. 2002. Penetration of engineered antibody fragments into the eye. Clin Exp Immunol 128: 67-74.
16. Lilyestrom WG, Yadav S, Shire SJ, Scherer TM,. 2013. Monoclonal antibody self-association, cluster formation, and rheology at high concentrations. J Phys Chem B 117: 6373-6384.
17. Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou Q,. 2007. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem 364: 8-18.
18. Yang X, Xu W, Dukleska S, Benchaar S, Mengisen S, Antochshuk V, Cheung J, Mann L, Babadjanova Z, Rowand J, Gunawan R, McCampbell A, Beaumont M, Meininger D, Richardson D, Ambrogelly A,. 2013. Developability studies before initiation of process development: Improving manufacturability of monoclonal antibodies. MAbs 5: 787-794.
19. Coloma MJ, Trinh RK, Martinez AR, Morrison SL,. 1999. Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1->6) dextran antibody. J Immunol 162: 2162-2170.
20. Huang L, Biolsi S, Bales KR, Kuchibhotla U,. 2006. Impact of variable domain glycosylation on antibody clearance: An LC/MS characterization. Anal Biochem 349: 197-207.
21. Grebenau RC, Goldenberg DM, Chang CH, Koch GA, Gold DV, Kunz A, Hansen HJ,. 1992. Microheterogeneity of a purified IgG1 due to asymmetric Fab glycosylation. Mol Immunol 29: 751-758.
22. Jefferis R., 2005. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 21: 11-16.
23. Gavel Y, von HG,. 1990. Sequence differences between glycosylated and non-glycosylated Asn-X-Thr/Ser acceptor sites: Implications for protein engineering. Protein Eng 3: 433-442.
24. Petrescu AJ, Milac AL, Petrescu SM, Dwek RA, Wormald MR,. 2004. Statistical analysis of the protein environment of N-glycosylation sites: Implications for occupancy, structure, and folding. Glycobiology 14: 103-114.
25. Stubenrauch K, Wessels U, Regula JT, Kettenberger H, Schleypen J, Kohnert U,. 2010. Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys. Drug Metab Dispos 38: 84-91.
26. Wang Y, Lu Q, Wu SL, Karger BL, Hancock WS,. 2011. Characterization and comparison of disulfide linkages and scrambling patterns in therapeutic monoclonal antibodies: Using LC-MS with electron transfer dissociation. Anal Chem 83: 3133-3140.
27. van der Neut KM, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, De Baets MH, van de Winkel JG, Aalberse RC, Parren PW,. 2007. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317: 1554-1557.
28. Zhang B, Yang Y, Yuk I, Pai R, McKay P, Eigenbrot C, Dennis M, Katta V, Francissen KC,. 2008. Unveiling a glycation hot spot in a recombinant humanized monoclonal antibody. Anal Chem 80: 2379-2390.
29. Miller AK, Hambly DM, Kerwin BA, Treuheit MJ, Gadgil HS,. 2011. Characterization of site-specific glycation during process development of a human therapeutic monoclonal antibody. J Pharm Sci 100: 2543-2550.
30. Quan C, Alcala E, Petkovska I, Matthews D, Canova-Davis E, Taticek R, Ma S,. 2008. A study in glycation of a therapeutic recombinant humanized monoclonal antibody: Where it is, how it got there, and how it affects charge-based behavior. Anal Biochem 373: 179-191.
31. Haberger M, Bomans K, Diepold K, Hook M, Gassner J, Schlothauer T, Zwick A, Spick C, Kepert JF, Hienz B, Wiedmann M, Beck H, Metzger P, Molhoj M, Knoblich C, Grauschopf U, Reusch D, Bulau P,. 2014. Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes. MAbs 6: 327-339.
32. Goetze AM, Liu YD, Arroll T, Chu L, Flynn GC,. 2012. Rates and impact of human antibody glycation in vivo. Glycobiology 22: 221-234.
33. Yuk IH, Zhang B, Yang Y, Dutina G, Leach KD, Vijayasankaran N, Shen AY, Andersen DC, Snedecor BR, Joly JC,. 2011. Controlling glycation of recombinant antibody in fed-batch cell cultures. Biotechnol Bioeng 108: 2600-2610.
34. Fischer S, Hoernschemeyer J, Mahler HC,. 2008. Glycation during storage and administration of monoclonal antibody formulations. Eur J Pharm Biopharm 70: 42-50.
35. Liu HF, Ma J, Winter C, Bayer R,. 2010. Recovery and purification process development for monoclonal antibody production. MAbs 2: 480-499.
36. Fesinmeyer RM, Hogan S, Saluja A, Brych SR, Kras E, Narhi LO, Brems DN, Gokarn YR,. 2009. Effect of ions on agitation- and temperature-induced aggregation reactions of antibodies. Pharm Res 26: 903-913.
37. Saluja A, Crampton S, Kras E, Fesinmeyer RM, Remmele RL Jr, Narhi LO, Brems DN, Gokarn YR,. 2009. Anion binding mediated precipitation of a peptibody. Pharm Res 26: 152-160.
38. Paterova J, Rembert KB, Heyda J, Kurra Y, Okur HI, Liu WR, Hilty C, Cremer PS, Jungwirth P,. 2013. Reversal of the hofmeister series: Specific ion effects on peptides. J Phys Chem B 117: 8150-8158.
39. Rembert KB, Paterova J, Heyda J, Hilty C, Jungwirth P, Cremer PS,. 2012. Molecular mechanisms of ion-specific effects on proteins. J Am Chem Soc 134: 10039-10046.
40. Sharma VK, Patapoff TW, Kabakoff B, Pai S, Hilario E, Zhang B, Li C, Borisov O, Kelley RF, Chorny I, Zhou JZ, Dill KA, Swartz TE,. 2014. In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability. Proc Natl Acad Sci USA 111: 18601-18606.
41. Moody TP, Kingsbury JS, Durant JA, Wilson TJ, Chase SF, Laue TM,. 2005. Valence and anion binding of bovine ribonuclease A between pH 6 and 8. Anal Biochem 336: 243-252.
42. Gokarn YR, Fesinmeyer RM, Saluja A, Razinkov V, Chase SF, Laue TM, Brems DN,. 2011. Effective charge measurements reveal selective and preferential accumulation of anions, but not cations, at the protein surface in dilute salt solutions. Protein Sci 20: 580-587.
43. Zhang L, Tan H, Fesinmeyer RM, Li C, Catrone D, Le D, Remmele RL Jr, Zhang J,. 2012. Antibody solubility behavior in monovalent salt solutions reveals specific anion effects at low ionic strength. J Pharm Sci 101: 965-977.
44. Singh SN, Yadav S, Shire SJ, Kalonia DS,. 2014. Dipole-dipole interaction in antibody solutions: Correlation with viscosity behavior at high concentration. Pharm Res 31: 2549-2558.
45. Yadav S, Laue TM, Kalonia DS, Singh SN, Shire SJ,. 2012. The influence of charge distribution on self-association and viscosity behavior of monoclonal antibody solutions. Mol Pharm 9: 791-802.
46. Yadav S, Sreedhara A, Kanai S, Liu J, Lien S, Lowman H, Kalonia DS, Shire SJ,. 2011. Establishing a link between amino acid sequences and self-associating and viscoelastic behavior of two closely related monoclonal antibodies. Pharm Res 28: 1750-1764.
47. Geiger T, Clarke S,. 1987. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem 262: 785-794.
48. Joshi AB, Sawai M, Kearney WR, Kirsch LE,. 2005. Studies on the mechanism of aspartic acid cleavage and glutamine deamidation in the acidic degradation of glucagon. J Pharm Sci 94: 1912-1927.
49. Clarke S., 1987. Propensity for spontaneous succinimide formation from aspartyl and asparaginyl residues in cellular proteins. Int J Pept Protein Res 30: 808-821.
50. Liu YD, van Enk JZ, Flynn GC,. 2009. Human antibody Fc deamidation in vivo. Biologicals 37: 313-322.
51. Huang L, Lu J, Wroblewski VJ, Beals JM, Riggin RM,. 2005. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal Chem 77: 1432-1439.
52. Walsh G, Jefferis R,. 2006. Post-translational modifications in the context of therapeutic proteins. Nat Biotech 24: 1241-1252.
53. Sydow JF, Lipsmeier F, Larraillet V, Hilger M, Mautz B, Molhoj M, Kuentzer J, Klostermann S, Schoch J, Voelger HR, Regula JT, Cramer P, Papadimitriou A, Kettenberger H,. 2014. Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions. PLoS One 9: e100736.
54. Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB,. 2001. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl 752: 233-245.
55. Cacia J, Keck R, Presta LG, Frenz J,. 1996. Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: Identification and effect on binding affinity. Biochemistry 35: 1897-1903.
56. Yan B, Steen S, Hambly D, Valliere-Douglass J, Vanden BT, Smallwood S, Yates Z, Arroll T, Han Y, Gadgil H, Latypov RF, Wallace A, Lim A, Kleemann GR, Wang W, Balland A,. 2009. Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. J Pharm Sci 98: 3509-3521.
57. Rehder DS, Chelius D, McAuley A, Dillon TM, Xiao G, Crouse-Zeineddini J, Vardanyan L, Perico N, Mukku V, Brems DN, Matsumura M, Bondarenko PV,. 2008. Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor immunoglobulin gamma2 antibody highlights the role avidity plays in antibody activity. Biochemistry 47: 2518-2530.
58. Sreedhara A, Cordoba A, Zhu Q, Kwong J, Liu J,. 2012. Characterization of the isomerization products of aspartate residues at two different sites in a monoclonal antibody. Pharm Res 29: 187-197.
59. Wakankar AA, Borchardt RT, Eigenbrot C, Shia S, Wang YJ, Shire SJ, Liu JL,. 2007. Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies. Biochemistry 46: 1534-1544.
60. Chu GC, Chelius D, Xiao G, Khor HK, Coulibaly S, Bondarenko PV,. 2007. Accumulation of succinimide in a recombinant monoclonal antibody in mildly acidic buffers under elevated temperatures. Pharm Res 24: 1145-1156.
61. Brinks V, Weinbuch D, Baker M, Dean Y, Stas P, Kostense S, Rup B, Jiskoot W,. 2013. Preclinical models used for immunogenicity prediction of therapeutic proteins. Pharm Res 30: 1719-1728.
62. Van WI, Gansemans Y, Parren PW, Stas P, Lasters I,. 2007. Immunogenicity screening in protein drug development. Expert Opin Biol Ther 7: 405-418.
63. Lundegaard C, Hoof I, Lund O, Nielsen M,. 2010. State of the art and challenges in sequence based T-cell epitope prediction. Immunome Res 6 (Suppl 2): S3.
64. Desmet J, Meersseman G, Boutonnet N, Pletinckx J, De CK, Debulpaep M, Braeckman T, Lasters I,. 2005. Anchor profiles of HLA-specific peptides: Analysis by a novel affinity scoring method and experimental validation. Proteins 58: 53-69.
65. Bian H, Hammer J,. 2004. Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE. Methods 34: 468-475.
66. Lata S, Bhasin M, Raghava GP,. 2007. Application of machine learning techniques in predicting MHC binders. Methods Mol Biol 409: 201-215.
67. Elfaki ME, Khalil EA, De Groot AS, Musa AM, Gutierrez A, Younis BM, Salih KA, El-Hassan AM,. 2012. Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines. Hum Vaccin Immunother 8: 1769-1774.
68. Holzhutter HG, Kloetzel PM,. 2000. A kinetic model of vertebrate 20S proteasome accounting for the generation of major proteolytic fragments from oligomeric peptide substrates. Biophys J 79: 1196-1205.
69. Davies MN, Sansom CE, Beazley C, Moss DS,. 2003. A novel predictive technique for the MHC class II peptide-binding interaction. Mol Med 9: 220-225.
70. De Groot AS, Jesdale BM, Szu E, Schafer JR, Chicz RM, Deocampo G,. 1997. An interactive web site providing major histocompatibility ligand predictions: Application to HIV research. AIDS Res Hum Retroviruses 13: 529-531.
71. Donnes P, Kohlbacher O,. 2006. SVMHC: A server for prediction of MHC-binding peptides. Nucleic Acids Res 34: W194-W197.
72. Rombach-Riegraf V, Karle AC, Wolf B, Sorde L, Koepke S, Gottlieb S, Krieg J, Djidja MC, Baban A, Spindeldreher S, Koulov AV, Kiessling A,. 2014. Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro. PLoS One 9: e86322.
73. Athmer L, Kindrachuk J, Georges F, Napper S,. 2002. The influence of protein structure on the products emerging from succinimide hydrolysis. J Biol Chem 277: 30502-30507.
74. Sinha S, Zhang L, Duan S, Williams TD, Vlasak J, Ionescu R, Topp EM,. 2009. Effect of protein structure on deamidation rate in the Fc fragment of an IgG1 monoclonal antibody. Protein Sci 18: 1573-1584.
75. Catak S, Monard G, Aviyente V, Ruiz-Lopez MF,. 2009. Deamidation of asparagine residues: Direct hydrolysis versus succinimide-mediated deamidation mechanisms. J Phys Chem A 113: 1111-1120.
76. Zhang YT, Hu J, Pace AL, Wong R, Wang YJ, Kao YH,. 2014. Characterization of asparagine 330 deamidation in an Fc-fragment of IgG1 using cation exchange chromatography and peptide mapping. J Chromatogr B Analyt Technol Biomed Life Sci 965C: 65-71.
77. Adem YT, Molina P, Liu H, Patapoff TW, Sreedhara A, Esue O,. 2014. Hexyl glucoside and hexyl maltoside inhibit light-induced oxidation of tryptophan. J Pharm Sci 103: 409-416.
78. Kishore RS, Kiese S, Fischer S, Pappenberger A, Grauschopf U, Mahler HC,. 2011. The degradation of polysorbates 20 and 80 and its potential impact on the stability of biotherapeutics. Pharm Res 28: 1194-1210.
79. Lam XM, Lai WG, Chan EK, Ling V, Hsu CC,. 2011. Site-specific tryptophan oxidation induced by autocatalytic reaction of polysorbate 20 in protein formulation. Pharm Res 28: 2543-2555.
80. Torosantucci R, Schoneich C, Jiskoot W,. 2014. Oxidation of therapeutic proteins and peptides: Structural and biological consequences. Pharm Res 31: 541-553.
81. Torosantucci R, Mozziconacci O, Sharov V, Schoneich C, Jiskoot W,. 2012. Chemical modifications in aggregates of recombinant human insulin induced by metal-catalyzed oxidation: Covalent cross-linking via michael addition to tyrosine oxidation products. Pharm Res 29: 2276-2293.
82. Torosantucci R, Sharov VS, van BM, Brinks V, Schoneich C, Jiskoot W,. 2013. Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon beta-1a: Potential implications for protein aggregation and immunogenicity. Mol Pharm 10: 2311-2322.
83. Li Y, Polozova A, Gruia F, Feng J,. 2014. Characterization of the degradation products of a color-changed monoclonal antibody: Tryptophan-derived chromophores. Anal Chem 86: 6850-6857.
84. Nieba L, Honegger A, Krebber C, Pluckthun A,. 1997. Disrupting the hydrophobic patches at the antibody variable/constant domain interface: Improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng 10: 435-444.
85. Chu JW, Yin J, Wang DI, Trout BL,. 2004. A structural and mechanistic study of the oxidation of methionine residues in hPTH(1-34) via experiments and simulations. Biochemistry 43: 14139-14148.
86. Ji JA, Zhang B, Cheng W, Wang YJ,. 2009. Methionine, tryptophan, and histidine oxidation in a model protein, PTH: Mechanisms and stabilization. J Pharm Sci 98: 4485-4500.
87. Li T, Chang B, Sloey C,. 2003. L-methionine as a stabilizer for NESP/EPO in HSA-free formulations. Patent US 20030104996 A1.
88. Anraku M, Tsurusaki Y, Watanabe H, Maruyama T, Kragh-Hansen U, Otagiri M,. 2004. Stabilizing mechanisms in commercial albumin preparations: Octanoate and N-acetyl-L-tryptophanate protect human serum albumin against heat and oxidative stress. Biochim Biophys Acta 1702: 9-17.
89. Zhang Q, Tang N, Brock JW, Mottaz HM, Ames JM, Baynes JW, Smith RD, Metz TO,. 2007. Enrichment and analysis of nonenzymatically glycated peptides: Boronate affinity chromatography coupled with electron-transfer dissociation mass spectrometry. J Proteome Res 6: 2323-2330.
90. Ma CD, Wang C, cevedo-Velez C, Gellman SH, Abbott NL,. 2015. Modulation of hydrophobic interactions by proximally immobilized ions. Nature 517: 347-350.
91. Lee CC, Perchiacca JM, Tessier PM,. 2013. Toward aggregation-resistant antibodies by design. Trends Biotechnol 31: 612-620.
92. Perchiacca JM, Ladiwala AR, Bhattacharya M, Tessier PM,. 2012. Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions. Protein Eng Des Sel 25: 591-601.
93. Haverick M, Mengisen S, Shameem M, Ambrogelly A,. 2014. Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: Overview and applications. MAbs 6: 852-858.
94. Queiroz JA, Tomaz CT, Cabral JM,. 2001. Hydrophobic interaction chromatography of proteins. J Biotechnol 87: 143-159.
95. Buck PM, Kumar S, Wang X, Agrawal NJ, Trout BL, Singh SK,. 2012. Computational methods to predict therapeutic protein aggregation. Methods Mol Biol 899: 425-451.
96. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL,. 2010. Prediction of aggregation prone regions of therapeutic proteins. J Phys Chem B 114: 6614-6624.
97. Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, Schwaiger M, Stubenrauch KG, Sustmann C, Thomas M, Scheuer W, Klein C,. 2011. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA 108: 11187-11192.
98. Chi EY, Krishnan S, Kendrick BS, Chang BS, Carpenter JF, Randolph TW,. 2003. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci 12: 903-913.
99. Rubin J, Sharma A, Linden L, Bommarius AS, Behrens SH,. 2014. Gauging colloidal and thermal stability in human IgG1-sugar solutions through diffusivity measurements. J Phys Chem B 118: 2803-2809.
100. Thakkar SV, Sahni N, Joshi SB, Kerwin BA, He F, Volkin DB, Middaugh CR,. 2013. Understanding the relevance of local conformational stability and dynamics to the aggregation propensity of an IgG1 and IgG2 monoclonal antibodies. Protein Sci 22: 1295-1305.
101. Ewert S, Huber T, Honegger A, Pluckthun A,. 2003. Biophysical properties of human antibody variable domains. J Mol Biol 325: 531-553.
102. Kayser V, Chennamsetty N, Voynov V, Helk B, Forrer K, Trout BL,. 2012. A screening tool for therapeutic monoclonal antibodies: Identifying the most stable protein and its best formulation based on thioflavin T binding. Biotechnol J 7: 127-132.
103. Lu ZJ, Deng SJ, Huang DG, He Y, Lei M, Zhou L, Jin P,. 2012. Frontier of therapeutic antibody discovery: The challenges and how to face them. World J Biol Chem 3: 187-196.
104. He F, Hogan S, Latypov RF, Narhi LO, Razinkov VI,. 2010. High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci 99: 1707-1720.
105. Thies MJ, Kammermeier R, Richter K, Buchner J,. 2001. The alternatively folded state of the antibody C(H)3 domain. J Mol Biol 309: 1077-1085.
106. Buchner J, Pastan I, Brinkmann U,. 1992. A method for increasing the yield of properly folded recombinant fusion proteins: Single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem 205: 263-270.
107. Vermeer AW, Norde W,. 2000. The thermal stability of immunoglobulin: Unfolding and aggregation of a multi-domain protein. Biophys J 78: 394-404.
108. Buchner J, Rudolph R,. 1991. Renaturation, purification and characterization of recombinant Fab-fragments produced in Escherichia coli. Biotechnology (NY) 9: 157-162.
109. Malik K, Matejtschuk P, Thelwell C, Burns CJ,. 2013. Differential scanning fluorimetry: Rapid screening of formulations that promote the stability of reference preparations. J Pharm Biomed Anal 77: 163-166.
110. Zhou C, Qi W, Neil LE, Carpenter JF,. 2015. Concomitant Raman spectroscopy and dynamic light scattering for characterization of therapeutic proteins at high concentrations. Anal Biochem 472: 7-20.
111. Geng SB, Cheung JK, Narasimhan C, Shameem M, Tessier PM,. 2014. Improving monoclonal antibody selection and engineering using measurements of colloidal protein interactions. J Pharm Sci 103: 3356-3363.
112. Tessier PM, Wu J, Dickinson CD,. 2014. Emerging methods for identifying monoclonal antibodies with low propensity to self-associate during the early discovery process. Expert Opin Drug Deliv 11: 461-465.
113. Nishi H, Miyajima M, Nakagami H, Noda M, Uchiyama S, Fukui K,. 2010. Phase separation of an IgG1 antibody solution under a low ionic strength condition. Pharm Res 27: 1348-1360.
114. Lehermayr C, Mahler HC, Mader K, Fischer S,. 2011. Assessment of net charge and protein-protein interactions of different monoclonal antibodies. J Pharm Sci 100: 2551-2562.
115. Collins KD., 2004. Ions from the Hofmeister series and osmolytes: Effects on proteins in solution and in the crystallization process. Methods 34: 300-311.
116. Zhang L, Zhang J,. 2012. Specific ion-protein interactions dictate solubility behavior of a monoclonal antibody at low salt concentrations. Mol Pharm 9: 2582-2590.
117. Arosio P, Jaquet B, Wu H, Morbidelli M,. 2012. On the role of salt type and concentration on the stability behavior of a monoclonal antibody solution. Biophys Chem 168-169: 19-27.
118. Shire SJ, Shahrokh Z, Liu J,. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93: 1390-1402.
119. Liu Y, Caffry I, Wu J, Geng SB, Jain T, Sun T, Reid F, Cao Y, Estep P, Yu Y, Vasquez M, Tessier PM, Xu Y,. 2014. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. MAbs 6: 483-492.
120. Connolly BD, Petry C, Yadav S, Demeule B, Ciaccio N, Moore JM, Shire SJ, Gokarn YR,. 2012. Weak interactions govern the viscosity of concentrated antibody solutions: High-throughput analysis using the diffusion interaction parameter. Biophys J 103: 69-78.
121. Saito S, Hasegawa J, Kobayashi N, Tomitsuka T, Uchiyama S, Fukui K,. 2013. Effects of ionic strength and sugars on the aggregation propensity of monoclonal antibodies: Influence of colloidal and conformational stabilities. Pharm Res 30: 1263-1280.
122. He F, Woods CE, Becker GW, Narhi LO, Razinkov VI,. 2011. High-throughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations. J Pharm Sci 100: 5126-5141.
123. Jayaraman J, Wu J, Brunelle MC, Cruz AM, Goldberg DS, Lobo B, Shah A, Tessier PM,. 2014. Plasmonic measurements of monoclonal antibody self-association using self-interaction nanoparticle spectroscopy. Biotechnol Bioeng 111: 1513-1520.
124. Sule SV, Dickinson CD, Lu J, Chow CK, Tessier PM,. 2013. Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates. Mol Pharm 10: 1322-1331.
125. Sun T, Reid F, Liu Y, Cao Y, Estep P, Nauman C, Xu Y,. 2013. High throughput detection of antibody self-interaction by bio-layer interferometry. MAbs 5: 838-841.
126. Li L, Kumar S, Buck PM, Burns C, Lavoie J, Singh SK, Warne NW, Nichols P, Luksha N, Boardman D,. 2014. Concentration dependent viscosity of monoclonal antibody solutions: Explaining experimental behavior in terms of molecular properties. Pharm Res 31: 3161-3178.
127. Yadav S, Shire SJ, Kalonia DS,. 2012. Viscosity behavior of high-concentration monoclonal antibody solutions: Correlation with interaction parameter and electroviscous effects. J Pharm Sci 101: 998-1011.
128. He F, Becker GW, Litowski JR, Narhi LO, Brems DN, Razinkov VI,. 2010. High-throughput dynamic light scattering method for measuring viscosity of concentrated protein solutions. Anal Biochem 399: 141-143.
129. Lavoisier A, Schlaeppi JM,. 2014. Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection. MAbs 7: 77-83.
130. Moore JM, Patapoff TW, Cromwell ME,. 1999. Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor. Biochemistry 38: 13960-13967.
131. Andersen JT, Dalhus B, Viuff D, Ravn BT, Gunnarsen KS, Plumridge A, Bunting K, Antunes F, Williamson R, Athwal S, Allan E, Evans L, Bjoras M, Kjaerulff S, Sleep D, Sandlie I, Cameron J,. 2014. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. J Biol Chem 289: 13492-13502.
132. Roopenian DC, Akilesh S,. 2007. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7: 715-725.
133. Schlothauer T, Rueger P, Stracke JO, Hertenberger H, Fingas F, Kling L, Emrich T, Drabner G, Seeber S, Auer J, Koch S, Papadimitriou A,. 2013. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. MAbs 5: 576-586.
134. Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, Hochman J, Prueksaritanont T,. 2011. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 39: 1469-1477.
135. Hotzel I, Theil FP, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, Fielder P, Carter PJ, Kelley RF,. 2012. A strategy for risk mitigation of antibodies with fast clearance. MAbs 4: 753-760.
136. Fenn S, Schiller CB, Griese JJ, Duerr H, Imhof-Jung S, Gassner C, Moelleken J, Regula JT, Schaefer W, Thomas M, Klein C, Hopfner KP, Kettenberger H,. 2013. Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain. PLoS One 8: e61953.
137. Schrama D.,Reisfeld R.A.,Becker J.C. Antibody targeted drugs as cancer therapeutics Nat Rev Drug Discov 2006 5 147-159